Final Height in Girls with Turner Syndrome after Growth Hormone Treatment ; Experience at National Children's Hospital

この論文にアクセスする

この論文をさがす

著者

    • TANAKA Toshiaki
    • Division of Endocrinology & Metabolism, National Children's Hospital
    • HORIKAWA Reiko
    • Division of Endocrinology & Metabolism, National Children's Hospital
    • TANAE Ayako
    • Division of Endocrinology & Metabolism, National Children's Hospital
    • HIBI Itsuro
    • Division of Endocrinology & Metabolism, National Children's Hospital

抄録

Twenty-four patients with Turner syndrome were treated with human growth hormone (GH) and reached their final height. Mean age was 11.7 years and mean height SDS was 0.28 SD for Japanese Turner standard at the start of GH treatment. Mean duration of GH treatment was 6.6 years and mean age at discontinuation of GH treatment was 18.6 years. Final height of all the patients was 146.9 ± 4.2 cm (140.5∼153.9 cm). Since predicted adult height (PAH) was 139.4 ± 5.8 cm (131.8∼155.0 cm), the benefit from growth-promoting therapy (final height - PAH) was 7.5 ± 4.6 cm (-1.4∼+15.2 cm). The final height in 10 patients (42%) exceeded the -2.0 SD value (147.9 cm) for normal girls. It can be concluded that the adult height in Turner syndrome was improved by GH treatment. However, final height was improved by starting pubertal induction later in addition to GH treatment in Japan. Early diagnosis and initiation of treatment with a higher dose of GH is important for adequate pubertal induction and final height.

収録刊行物

  • Clinical pediatric endocrinology

    Clinical pediatric endocrinology 9(1), 41-46, 2000-06-01

    日本小児内分泌学会

参考文献:  15件中 1-15件 を表示

被引用文献:  3件中 1-3件 を表示

各種コード

  • NII論文ID(NAID)
    10013215123
  • NII書誌ID(NCID)
    AA11006467
  • 本文言語コード
    ENG
  • 資料種別
    REV
  • ISSN
    09185739
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ